Carbapenem Market (By Product Type; By Indication Product Type: Urinary Tract Infections, Bloodstream Infections; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Carbapenem Market 

5.1. COVID-19 Landscape: Carbapenem Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Carbapenem Market, By Product Type

8.1. Carbapenem Market, by Product Type, 2022-2030

8.1.1 Branded Products

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Generic Products

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Carbapenem Market, By Application

9.1. Carbapenem Market, by Application, 2022-2030

9.1.1. Urinary Tract Infections (UTIs)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Bloodstream Infections

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Intra-abdominal Infections

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Pneumonia

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Acute Pelvic Infections

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Carbapenem Market, By Distribution Channel 

10.1. Carbapenem Market, by Distribution Channel, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Carbapenem Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. Menarini Group

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Pfizer Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sun Pharmaceutical Industries Ltd

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Lupin

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Kopran Limited

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Aurobindo Pharma

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Daewoong Pharmaceuticals Co., Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Shenzhen Haibin Pharmaceutical Co. Ltd.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Merck & Co., Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms